NC-QUINTILES-NCTA
Expression Analysis (EA), a Quintiles company, today announced the winners of a grant program that provides scientists with leading-edge products and services to advance genomics research. In this sixth year of the program, EA and co-sponsor, Illumina, awarded two fully funded research grants to investigate genomic data locked within Formalin-Fixed, Paraffin Embedded (FFPE) tumor samples – a largely untapped data pool that can help enhance researchers’ understanding of cancer biology.
After a rigorous review of nearly 700 submissions by a distinguished panel of judges, two researchers were selected to receive grants. The recipients include:
- Professor Anne Bowcock, Ph.D., chair of Cancer Genomics at Imperial College London, who will profile a specific subset of metastatic colon cancers – those that metastasize to the lung – for CpG methylation and transcriptomic alterations. Her research, driven in partnership with Sing Yu Moorcraft and Ian Chau, will help create a comprehensive profile of genomic changes that occur during tumor evolution. These results could help inform the identification of drugs that target key abnormalities and molecular drivers of this often-deadly cancer. They could also help identify potential prognostic or predictive biomarkers that can assist physicians in determining optimal treatment approaches.
- Dr. Zhiqing Huang, M.D., Ph.D., senior research scientist at the Duke University Medical Center, will investigate genome-scale DNA methylation and RNA expression changes in epithelial ovarian cancer to help explain ovarian cancer recurrence and the contribution of the tumor microenvironment. These results could help identify new biomarkers for ovarian cancer diagnosis and prognosis, especially among the 20-30 percent of ovarian cancer patients whose tumors do not produce CA125 – a key biomarker for ovarian cancer diagnosis known today. In addition, they hope to identify more relevant targets for chemotherapy or gene-specific therapy.
“Genomic research has the power to transform our knowledge of cancer biology and is instrumental in identifying biomarkers that lead to the development of life-saving and life-enhancing therapies,” said Kellie Yarnell, vice president for Genomic Operations at EA. “Through this grant program, we will help support the work of Dr. Bowcock and Dr. Huang, whose research could one day lead to important advances in the fights against colorectal and ovarian cancers.”
“We are honored to support the efforts of Dr. Bowcock and Dr. Huang in their quests to better understand the underlying science of colon and ovarian cancers. We hope that their research yields insights which will one day improve outcomes for individuals with these devastating diseases,” said Tina Nova, senior vice president and general manager, oncology for Illumina.
About EA
EA, a Quintiles company, provides cutting-edge genomic sequencing, gene expression, genotyping, and bioinformatics services to the world’s largest pharmaceutical companies, diagnostic test developers, government agencies, and academic labs. Projects are conducted under clinical-grade quality control, ensured through CLIA certification, GCP compliance, and adherence to CLSI guidelines as applicable to the testing performed. EA’s bioinformatics staff are key contributors to the Food and Drug Administration’s MicroArray Quality Control (MAQC) and Sequencing Quality Control (SEQC) studies, which aim to improve standards and quality measures for reliable use of next-generation sequencing and gene expression technologies in clinical practice and regulatory decision-making. As part of its mission to improve human health, EA has donated more than $2.8 million towards academic genomic research grants and its “Leave Your Fingerprint on the Cure” Program for pediatric cancer hosted at the American Society for Human Genetics annual meeting.
About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com .
Click here to subscribe to Mobile Alerts for Quintiles.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150115005099/en/
Contact:
Quintiles
Mari Mansfield, Media Relations
+1-919-998-2639
(office), +1-919-259-3298 (mobile)
mari.mansfield@quintiles.com
or
Karl
Deonanan, Investor Relations
+1-919-998-2789
InvestorRelations@quintiles.com
www.quintiles.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
The Coca-Cola Company Names New Leader for Europe Operating Unit18.7.2025 21:00:00 CEST | Press release
The Coca-Cola Company today announced that Luisa Ortega will become president of the Europe operating unit effective Sept. 1, succeeding Nikos Koumettis, who will retire in 2026 after a 25-year career with the company. Koumettis will remain with the company through Feb. 28, 2026, as a senior advisor. He will also serve on the board of directors of Hindustan Coca-Cola Beverages Pvt. Ltd., a company-owned bottler in India. Ortega joined Coca-Cola in 2019 and currently serves as president of the Africa operating unit. In this role, she leads a complex business that operates across 54 markets. Koumettis has led the Europe operating unit since it was created in 2021. “Luisa has done an outstanding job leading our African business, where our system has continued to make major investments to serve growing markets on the continent,” said Henrique Braun, Executive Vice President and Chief Operating Officer of The Coca-Cola Company. “As head of Europe, she will bring great international experien
NFL Running Back Derrick Henry Joins Amazfit as Athlete Ambassador18.7.2025 15:00:00 CEST | Press release
Henry to utilize Amazfit products to optimize health, recovery and performance as he enters his 10th NFL season Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), announced Baltimore Ravens running back Derrick Henry as the newest elite athlete to join its growing roster of ambassadors. Known for his rare combination of speed and strength, Henry will utilize Amazfit wearables to power every phase of his training, recovery and sleep as he prepares for his 10th NFL season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250718322498/en/ Derrick Henry is the newest elite athlete to join Amazfit's growing roster of ambassadors. As one of the most prolific running backs of his generation, Henry has amassed an impressive array of accolades during his career, including NFL Offensive Player of the Year, two rushing titles, and five Pro Bowl selections. With Amazfit as his official smart wearable partne
Qualcomm Announces Quarterly Cash Dividend18.7.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on September 25, 2025, to stockholders of record at the close of business on September 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensin
MultiBank Group Confirms $MBG Token Listings on MEXC and Gate.io on TGE Day in Addition to MultiBank.io and Uniswap18.7.2025 14:34:00 CEST | Press release
MultiBank Group, the world’s largest & most regulated financial derivatives institution, is proud to announce that its highly anticipated $MBG Token will be listed on two new major global cryptocurrency exchanges — MEXC and Gate.io — on the day of its official Token Generation Event (TGE), July 22, 2025, in addition to MultiBank.io and Uniswap. The $MBG Token will go live on: MultiBank.ioGate.ioMEXCUniswap This new dual listing will allow millions of users across both exchanges to seamlessly access and trade $MBG using their existing accounts, ensuring immediate market participation at launch. The Token Generation Event (TGE) is now approaching following the successful completion of two pre-sale rounds, where MultiBank Group issued 7 million tokens in Round 1 and 3 million tokens in Round 2 — both of which sold out within minutes. Naser Taher, Chairman and Founder of MultiBank Group said “With $MBG, we’re introducing a utility token built to deliver real-world value, transparency, and
SLB Announces Second-Quarter 2025 Results18.7.2025 12:50:00 CEST | Press release
Revenue of $8.55 billion increased 1% sequentially and decreased 6% year on year GAAP EPS of $0.74 increased 28% sequentially and decreased 4% year on year EPS, excluding charges and credits, of $0.74 increased 3% sequentially and decreased 13% year on year Net income attributable to SLB of $1.01 billion increased 27% sequentially and decreased 9% year on year Adjusted EBITDA of $2.05 billion increased 2% sequentially and decreased 10% year on year Cash flow from operations was $1.14 billion and free cash flow was $622 million Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the second-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716727689/en/ The exterior of the SLB headquarters in Houston, Texas. Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2025Mar. 31, 2025Jun. 30, 2024SequentialYear-on-yearReve
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum